medidata

<u>FOR IMMEDIATE RELEASE</u>

**Medidata's Cloud-Based Platform Powers Next-Generation
Immunotherapy Vaccine Trial in Australia**

*Admedus Adopts the Medidata Clinical Cloud® to Bring Greater Speed and
Efficiency to Its Genital Herpes Therapeutic Vaccine Study*

NEW YORK, N.Y. – August XX, 2015 – <u>Medidata</u> (NASDAQ: MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that <u>Admedus Ltd (ASX: AHZ)</u>, a specialist healthcare company that delivers innovative medical technologies and devices, has adopted its industry-leading cloud technology. The Australian-based listed company is leveraging the <u>Medidata Clinical Cloud</u>® platform to bring speed, efficiencies and enhanced decision-making to its clinical development of a therapeutic vaccine for genital herpes (HSV-2), aimed at activating a T-cell response against the virus to benefit sufferers.

"It is estimated that up to 20 million people worldwide are newly infected with HSV-2 each year," said Admedus CEO Lee Rodne. "Our potential therapeutic vaccine could have life-changing effects for these people and future generations. Admedus' study is currently progressing well and we are expecting some interim results from our Phase II clinical trial later this year."

He added: "Working with Medidata offers a huge advantage for us from a clinical perspective. By marrying our scientific expertise with Medidata's cloud-based technology, we expect better trial speed and better data, both of which help enhance decision-making."

Admedus is an R&D leader in tissue engineering for regenerative medicine and immunotherapy for therapeutic vaccines. To streamline clinical trial operations and improve data accessibility in a Phase II study of its novel therapeutic vaccine against genital herpes, the global healthcare group is collaborating with Clinical Network Services (CNS) Pty Ltd—an integrated clinical and product service group, and Medidata CRO partner—and harnessing Medidata's cloud-based technology for electronic data capture and management (<u>Medidata Rave</u>®).

Takeru Yamamoto, Medidata's managing director of the Asia-Pacific (APAC) region, said, "We're excited to be working alongside such a forward-thinking organization as Admedus, especially as we expand into the clinical trial landscape in Australia. We share Admedus' mission of making a difference in the outcomes and quality of life for patients—both in Australia and around the globe—and are proud to power their research as they continue to develop innovative immunotherapies to help treat and prevent infectious diseases."

About Admedus
Admedus (ASX: AHZ) is a specialist global healthcare company. Our focus is on investing in and developing next generation technologies. The Company has assets in research & development technology platforms, through clinical development as well as sales, marketing and distribution with a global sales force. Admedus continues to commercialise products from its innovative tissue engineering platform technology, building on the success of CardioCel. Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus. Further information on the company can be found at admedus.com

About CNS
Clinical Network Services (CNS) is an integrated service group focused on product development headquartered in Australia with offices in New Zealand, the UK and the USA, who create value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner. CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with our committed, highly experienced Australian/New Zealand clinical services and biometrics team. CNS' regional clinical advantage is driven by the extremely pragmatic regulatory environment in Australia and New Zealand that makes it possible for clients to enter the clinic quickly, without prior regulatory approval.

CNS offers a uniquely differentiated, customer-orientated, suite of services to clients which enables CNS to guide products efficiently through critical post-discovery development and into initial human trials. Throughout, CNS takes a global development/ regulatory strategic approach to ensure that value is added at every stage of the product development life cycle.

Further information about CNS and its intelligent development services can be found at www.clinical.net.au

About Medidata
Medidata is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud® brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of global customers, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations.

Medidata Contacts
Investor: Hulus Alpay, Medidata Solutions, +1 212-419-1025,
halpay@mdsol.com
Media – Americas & EMEA: Nicole Pariser, Medidata Solutions, 212-659-
1069, npariser@mdsol.com
Media – APAC: Chitose Yamada, Medidata Solutions, +81 3-4588 0895,
cyamada@mdsol.com

Admedus Contacts
Investor: Julian Chick, Admedus, (0)8 9266 0100, jchick@admedus.com
Media: Shevaun Cooper, Admedus, (0)8 9266 0100, scooper@admedus.com

CNS Contact
Investor/Media: Russell Neal, +61 (0)7 3719 6000,
russell.neal@clinical.net.au